Bio Pharma Dive
JANUARY 8, 2021
With additional financing, Celularity will have $372 million to back development of experimental off-the-shelf treatments for cancer and autoimmune diseases.
World of DTC Marketing
JANUARY 4, 2021
KEY TAKEAWAY: Consumer behavior has changed due to the pandemic, and DTC marketers should be aware of how consumers will evaluate and choose prescription drugs. Many organizations have postponed market research due to the pandemic but knowledgeable DTC marketers should be aware of the progressive trends in healthcare. Here’s my list: 1ne: DTC should focus more on providing health information about advertised medications and less on “selling.” The overwhelming majority of consum
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
JANUARY 4, 2021
KRAS mutations are found in several hard-to-treat cancers
XTalks
JANUARY 8, 2021
The US Food and Drug Administration (FDA) released a statement this week about dosing schedules for COVID-19 vaccines, saying that any dose changes would be premature. In the statement , the FDA said that it wants to “remind the public about the importance of receiving COVID-19 vaccines according to how they’ve been authorized by the FDA in order to safely receive the level of protection observed in the large randomized trials supporting their effectiveness.”.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JANUARY 5, 2021
By March, the FDA expects to conclude reviews of key drugs for heart failure, Duchenne's and multiple myeloma, as well as decide on whether to clear Biogen's controversial Alzheimer's treatment.
World of DTC Marketing
JANUARY 8, 2021
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. Wall Street has been speculating for a long time on which pharma company is going to make the most from the development of a Covid-19 vaccine.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
JANUARY 4, 2021
Shot was approved by MHRA on 30 December
Bio Pharma Dive
JANUARY 7, 2021
The first patient enrolled in a Phase 3 trial of Pfizer's treatment was given the experimental one-time therapy on Dec. 29.
World of DTC Marketing
JANUARY 7, 2021
MINUTE READ: Big pharma should take a good, hard look at small biotech companies and try to better understand how they succeed and are able to make strategic decisions faster without multi-levels of bureaucracy. This week a person with whom I have the highest level of respect because of her emotional and marketing intelligence landed a position with a small biotech company as Global Marketing Director.
BioPharma Reporter
JANUARY 7, 2021
The World Health Organizationâs vaccine advisory group recommends the two doses of the Pfizer/BioNTech vaccine should be delivered 21 to 28 days apart: although it adds that the maximum time period between doses could be up to six weeks in some situations.
Pharma Times
JANUARY 5, 2021
Company is aiming for approval in the adjuvant setting
Bio Pharma Dive
JANUARY 8, 2021
Gene therapy developers will need to address a series of setbacks that have shaded optimism in the sector's fast growth.
BioSpace
JANUARY 3, 2021
As the sun rose on a new year, approximately 70 companies raised the price of hundreds of prescription drugs by an average of 3.3%.
World of DTC Marketing
JANUARY 6, 2021
PONTIFICATION: Healthcare agencies need to be the agents of change and lead by example. Speculation or buying into the temporary changes brought on by the pandemic are unrealistic. I just finished reading the latest edition of MedAd News and besides being really dip pointed with the content I was extremely put back by the section on agency people speculating on the changes brought on by the pandemic.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Mirror
JANUARY 6, 2021
Infant nutrition, outside of breastfeeding, has become a hot topic recently. Families are taking a hard look at how baby formulas’ ingredients impact their children’s health and development. Concerns and Contamination Every day American parents and caregivers reach for over-the-counter baby formulas and are surprised to find chemicals, additives, and other ingredients that are known to cause health concerns.
Bio Pharma Dive
JANUARY 4, 2021
With no decision from the FDA on approval of an experimental cancer cell therapy, an agreement by Bristol Myers to pay out more money as part of its Celgene acquisition fell apart.
BioSpace
JANUARY 7, 2021
Biotech growth in China continued at a rapid pace in 2020, despite COVID-19, which emerged from that country to become a global pandemic. Opportunities in China remain good and are expected to continue.
Pharma Times
JANUARY 8, 2021
Anti-inflammatory drugs also accelerated patients' recovery times
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
JANUARY 5, 2021
Tinkering with the dosing schedule of COVID-19 vaccines runs a “significant risk” to public health, the FDA has warned in a statement after the UK announced plans to prioritise the first doses of two approved shots. The regulator made its comments after the UK announced a policy of stretching the gap between doses of the vaccine to up to 12 weeks to ensure maximum coverage of vulnerable groups.
Bio Pharma Dive
JANUARY 5, 2021
Founded by industry veteran Arie Belldegrun's venture capital firm, IconOVir Bio raised $77 million to push its lead drug — derived from the common cold — into clinical testing.
BioSpace
JANUARY 5, 2021
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Pharma Times
JANUARY 4, 2021
Submission based on results from phase I CHRYSALIS study
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JANUARY 8, 2021
The Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in the UK and South Africa, according to research from the drugs giant. Findings of the lab study posted online have not yet been peer reviewed but provide some reassurance for countries like the UK, which are relying on vaccines to bring the pandemic under control.
Bio Pharma Dive
JANUARY 7, 2021
Company executives, however, blamed "improbably bad luck" for study enrollment that resulted in more older patients with milder disease receiving placebo, and pledged to press on.
BioSpace
JANUARY 3, 2021
As Operation Warp Speed struggles to ramp up vaccinations, one of the approaches under consideration is cutting the doses of the Moderna vaccine.
Pharma Times
JANUARY 5, 2021
Key focus of the deal is focal-onset seizure treatment cenobamate
pharmaphorum
JANUARY 6, 2021
Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team culture makes it work. This thought leadership series has been paid and developed by Kite, a Gilead Company. In 2018, we were preparing to build a European facility to produce individualised cell therapies for the treatment of cancer.
Bio Pharma Dive
JANUARY 6, 2021
A Series B investment in Senti Biosciences will support the startup's research on off-the-shelf candidates, as Bayer places another bet on cell therapy.
BioSpace
JANUARY 7, 2021
BioSpace spoke to executives from four companies about their expectations for the conference and the coming year.
Pharma Times
JANUARY 6, 2021
Test can give accurate results in under five minutes, according to researchers
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
362 
Let's personalize your content